

Results of 2025 Annual General Meeting

In accordance with ASX Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001 (Cth), the attached information is provided in relation to the resolutions put to shareholders of Genetic Signatures Limited (ASX: GSS) at its 2025 Annual General Meeting held earlier today.

– END –

Announcement authorised for release by the Company Secretary of Genetic Signatures Limited.

For further information, see our website (www.geneticsignatures.com) or contact us:

Allison Rossiter

Chief Executive Officer

allison.rossiter@geneticsignatures.com

T: +61 (0)2 9870 7580

Karl Pechmann

Chief Financial Officer

karl.pechmann@geneticsignatures.com

About Genetic Signatures Limited:

Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, 3base®. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen*™ brand. Genetic Signatures' proprietary MDx 3base® platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospitals and pathology laboratories undertaking infectious disease screening. Genetic Signatures is leveraging strong COVID-19 related sales of its *EasyScreen*™ respiratory kits and the growing interest in its gastroenteritis products to further commercialise its 3base® technology to rapidly and cost effectively screen for a wide array of infectious pathogens including antibiotic resistant bacteria, sexually transmitted infections, meningitis and mosquito borne viral diseases.

**Genetic Signatures Limited
Annual General Meeting
Monday, 17 November 2025
Results of Meeting**

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result	If s250U applies
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried	
1. Re-election of Director – Dr Neil Gunn	Ordinary	95,186,991 89.79%	10,532,572 9.94%	289,179 0.27%	759,348	144,804,067 93.22%	10,532,572 6.78%	759,348	Carried	N/A
2. Re-election of Director – Ms Caroline Waldron	Ordinary	96,306,561 90.40%	9,943,807 9.33%	289,179 0.27%	228,543	145,923,637 93.62%	9,943,807 6.38%	228,543	Carried	N/A
3. Adoption of the Remuneration Report	Ordinary	91,683,737 88.57%	11,553,875 11.16%	282,276 0.27%	725,688	139,812,233 91.47%	13,035,552 8.53%	725,688	Carried	NO
4. Approval to Grant Restricted Rights to Director, Ms Anne Lockwood	Ordinary	93,628,452 87.89%	12,626,585 11.85%	282,276 0.26%	208,263	141,756,948 90.95%	14,108,262 9.05%	208,263	Carried	N/A
5. Approval to Grant Restricted Rights to Director, Dr Jenny Harry	Ordinary	93,628,452 87.89%	12,626,585 11.85%	282,276 0.26%	208,263	141,756,948 90.95%	14,108,262 9.05%	208,263	Carried	N/A

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.